# Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression

> **NCT03014297** · PHASE1 · TERMINATED · sponsor: **Lowell Anthony, MD** · enrollment: 17 (actual)

## Conditions studied

- Neuroendocrine Tumors
- Everolimus

## Interventions

- **DRUG:** everolimus
- **DRUG:** fosbretabulin

## Key facts

- **NCT ID:** NCT03014297
- **Lead sponsor:** Lowell Anthony, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-06
- **Primary completion:** 2018-06-05
- **Final completion:** 2018-11-16
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Part I completed. Part 2 will not be done due to sponsor decision.
- **Last updated:** 2019-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03014297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03014297, "Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03014297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*